FG Onco Cisplatin
Pharmacogenetics of cisplatin treatment
Cisplatin is an antineoplastic drug used in the treatment of sarcomas, some carcinomas (for example, lung cancer of small cells and ovarian cancer), lymphomas, and in the germ cell tumor. The gene encoding the enzyme thiopurine methyltransferase (TPMT) is located on the short arm of chromosome 6 in the 6p22.3 region and certain variants in there are associated with a reduction in enzyme activity. These mutations in the TPMT gene are responsible for the variation in response to cisplatin treatment and a significant percentage of serious adverse reactions to this drug.
The genetic profile FG – Onco Cisplatin studies the main allelic variants of the TPMT gene with known clinical relevance. Together, these mutations are responsible for more than 95% of the reduction of TPMT enzyme activity. The aim of the analysis is to identify those patients with a decrease in TPMT enzyme activity and an increased likelihood of developing serious side effects or toxicity to cisplatin treatment.
• Patients on pharmacological treatment who wish to customize medication based on their genetic profile
• Patients in whom pharmacological treatments do not show the expected results
Next Generation Sequencing (NGS)
• Guaranteed from the experience of the Synlab group, the absolute European leader in laboratory diagnosis.
• Detailed report including, in addition to the type of metabolism of each enzyme, which drugs can generate toxic effects and adverse reactions, as well as dose recommendations.
• Information provided by the analysis allows the selection of the most appropriate drug, and determines the most appropriate dose for each patient.
• Genetic counseling available at no additional cost, according to the needs of each client.
DOCUMENTATION – Available on Extranet for clients:
• Informed Consent
• Clinical Questionnaire
• Fasting is not necessary for the test.